Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 7th Conference on Retroviruses and Opportunistic Infections
Session 30
State of the Art Lecture: HIV Entry and Its Inhibition
Peter Kim
Howard Hughes Med. Inst., Whitehead Inst. for Biomed. Res., MIT, Cambridge, MA

January 31, 2000

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Click Here to Listen to the Original Lecture


This presentation reviewed the exciting area of HIV entry and fusion as a target for antiviral drug development. For HIV to establish infection, it must first attach to a host cell and fuse with that cell's outer membrane. Two HIV envelope proteins, gp120 and gp41 -- which mediate binding to cellular receptors and fusion respectively -- facilitate the entry of HIV into the cell. An inhibitor of this process, T20, is already in clinical trials and has shown potent antiretroviral activity even when given to patients who have multiply resistant virus. However, drawbacks to this drug (the first of its class) include the need to administer it intravenously as well as the relatively high doses required for it to achieve inhibition of the binding.

In his presentation, Dr. Kim described how his laboratory has characterized the structure of gp41, especially in the crucial step just before HIV-cellular fusion. Using this information, he and his colleagues have identified a "pocket" on the molecule that would be an ideal target for binding and inhibition of gp41 action. They are currently screening various peptides for their ability to bind to this pocket, which eventually he believes will lead to the discovery of orally bioavailable blockers of HIV entry into cells.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More Research on HIV/AIDS
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement